The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Janux Therapeutics Inc (NASDAQ: JANX) closed at $32.05 in the last session, down -3.46% from day before closing price of $33.20. In other words, the price has decreased by -$3.46 from its previous closing price. On the day, 1.05 million shares were traded. JANX stock price reached its highest trading level at $33.05 during the session, while it also had its lowest trading level at $31.3375.
Ratios:
We take a closer look at JANX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 59.21 and its Current Ratio is at 59.21. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 03, 2024, Reiterated its Buy rating but revised its target price to $70 from $63 previously.
On December 03, 2024, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $82 to $100.
On November 22, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $79.Leerink Partners initiated its Outperform rating on November 22, 2024, with a $79 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 01 ’25 when ANDREW MEYER bought 3,333 shares for $33.20 per share.
Meyer Andrew Hollman sold 3,334 shares of JANX for $100,020 on Apr 21 ’25. The Chief Business Officer now owns 82,139 shares after completing the transaction at $30.00 per share. On Apr 21 ’25, another insider, ANDREW MEYER, who serves as the Officer of the company, bought 3,334 shares for $29.69 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 1894318464 and an Enterprise Value of 892171968. For the stock, the TTM Price-to-Sale (P/S) ratio is 178.88 while its Price-to-Book (P/B) ratio in mrq is 1.85. Its current Enterprise Value per Revenue stands at 84.263 whereas that against EBITDA is -9.218.
Stock Price History:
The Beta on a monthly basis for JANX is 3.24, which has changed by -0.50524855 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $22.52. The 50-Day Moving Average of the stock is 5.69%, while the 200-Day Moving Average is calculated to be -25.96%.
Shares Statistics:
According to the various share statistics, JANX traded on average about 898.35K shares per day over the past 3-months and 646840 shares per day over the past 10 days. A total of 59.06M shares are outstanding, with a floating share count of 49.40M. Insiders hold about 16.42% of the company’s shares, while institutions hold 107.86% stake in the company. Shares short for JANX as of 1744675200 were 9340605 with a Short Ratio of 10.40, compared to 1741910400 on 10497950. Therefore, it implies a Short% of Shares Outstanding of 9340605 and a Short% of Float of 28.02.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of Janux Therapeutics Inc (JANX) is currently shaped by the ongoing analysis conducted by 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.46, with high estimates of -$0.31 and low estimates of -$0.69.
Analysts are recommending an EPS of between -$1.29 and -$3.32 for the fiscal current year, implying an average EPS of -$2.08. EPS for the following year is -$2.67, with 7.0 analysts recommending between -$1.55 and -$4.84.
